Tuesday, April 28, 2026
28.7 C
Bengaluru

Subhendu K Datta has taken on a new role as Senior Vice President (Sales...

In his new position, he will lead teams across the region with a focus...

Tez Health and the New Race to Bring Healthcare Home

Tez Health and the New Race to Bring Healthcare...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

The Semaglutide Gold Rush: Miracle Cure or Market Mirage?

The Indian Pharmaceutical Market (IPM) has entered a definitive...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Topics

Don't Miss MedicinMan Updates

Hot this week

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

Blinkit, Zepto, Instamart: Who Will Own India’s At‑Home Diagnostics Market?

India’s diagnostics market is undergoing a quiet but profound...
spot_img

Follow Us

Popular Categories

Video Insights

spot_imgspot_img

Headlines

Will the GLP Battle Now Shift from Injectable to Oral?

In India’s million-strong retail pharmacy universe, oral weight-loss pills won’t wait for prescriptions—and the industry needs to prepare for...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business unit. It was a scientific outpost. I entered this field when...

Exclusive Articles

The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune

In the pharmaceutical world, we often focus on the "Top Line": India’s domestic market at $25 billion (₹2.12 lakh...

Music

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune

In the pharmaceutical world, we often focus on the...

Food

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune

In the pharmaceutical world, we often focus on the...

A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act

Sun Pharma’s Odyssey and Organon’s Second Act – And...

The Semaglutide Gold Rush: Miracle Cure or Market Mirage?

The Indian Pharmaceutical Market (IPM) has entered a definitive...

Samuel Paradise

Manuela Cole

Keisha Adams

George Pharell

spot_imgspot_img

Leaders Speak

Business leaders sharing their insights

K. Hariram
8 POSTS
Raja Reddy
5 POSTS